Aspirin
/ Aspirin / Caffeine, Aspirin /, Aspirin / Butalbital / Caffeine, Aspirin / Butalbital / Caffeine /, Axotal, Codoxy, Darvon, Darvon W/ Asa, Equagesic, Excedrin (migraine Relief), Lanorinal, Micrainin, Orphengesic, Percodan, Percodan-demi, Pravigard, Q-gesic, Robaxisal, Roxiprin, Soma, Synalgos-dc, Talwin, Vazalore, W/ Asa, Yosprala (aspirin) is a small molecule pharmaceutical. Aspirin was first approved as Codeine, aspirin, apap formula no. 4 on 1982-01-01. It is used to treat fever, gout, inflammation, osteoarthritis, and pain amongst others in the USA. The pharmaceutical is active against prostaglandin G/H synthase 2 and prostaglandin G/H synthase 1. In addition, it is known to target acid-sensing ion channel 3, transient receptor potential cation channel subfamily V member 3, and N-formyl peptide receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 10 person ansi | OTC monograph final | 2010-06-07 |
| 25 person ansi | OTC monograph final | 2010-06-07 |
| 50 person ansi | OTC monograph final | 2010-06-07 |
| acetaminophen 250mg aspirin 250mg caffeine 65mg | C200263 | 2024-12-26 |
| acetaminophen aspirin and caffeine | ANDA | 2024-03-05 |
| acetaminophen aspirin caffeine | ANDA | 2024-11-18 |
| acetaminophen, aspirin and caffeine | ANDA | 2024-12-10 |
| acetaminophen, aspirin, caffeine | C200263 | 2025-02-11 |
| acetylsalicylic acid | Export only | 2025-01-15 |
| ache and pain relief to go | OTC monograph not final | 2014-10-08 |
Show 468 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
ATC Codes
M: Musculo-skeletal system drugs
— M03: Muscle relaxants
— M03B: Muscle relaxants, centrally acting agents
— M03BA: Carbamic acid esters, centrally acting muscle relaxants
— M03BA02: Carisoprodol
— M03BA52: Carisoprodol, combinations excl. psycholeptics
— M03BA72: Carisoprodol, combinations with psycholeptics
HCPCS
Code | Description |
|---|---|
| G2128 | Documentation of medical reason(s) for not on a daily aspirin or other antiplatelet (e.g. history of gastrointestinal bleed, intra-cranial bleed, blood disorders, idiopathic thrombocytopenic purpura (itp), gastric bypass or documentation of active anticoagulant use during the measurement period) |
| G8598 | Aspirin or another antiplatelet therapy used |
| G8599 | Aspirin or another antiplatelet therapy not used, reason not given |
| G9277 | Documentation that the patient is on daily aspirin or anti-platelet or has documentation of a valid contraindication or exception to aspirin/anti-platelet; contraindications/exceptions include anti-coagulant use, allergy to aspirin or anti-platelets, history of gastrointestinal bleed and bleeding disorder; additionally, the following exceptions documented by the physician as a reason for not taking daily aspirin or anti-platelet are acceptable (use of non-steroidal anti-inflammatory agents, documented risk for drug interaction, uncontrolled hypertension defined as >180 systolic or >110 diastolic or gastroesophageal reflux) |
| G9278 | Documentation that the patient is not on daily aspirin or anti-platelet regimen |
| G9793 | Patient is currently on a daily aspirin or other antiplatelet |
| G9794 | Documentation of medical reason(s) for not on a daily aspirin or other antiplatelet (e.g., history of gastrointestinal bleed, intra-cranial bleed, idiopathic thrombocytopenic purpura (itp), gastric bypass or documentation of active anticoagulant use during the measurement period) |
| G9795 | Patient is not currently on a daily aspirin or other antiplatelet |
| M1055 | Aspirin or another antiplatelet therapy used |
| M1056 | Prescribed anticoagulant medication during the performance period, history of gi bleeding, history of intracranial bleeding, bleeding disorder and specific provider documented reasons: allergy to aspirin or anti-platelets, use of non-steroidal anti-inflammatory agents, drug-drug interaction, uncontrolled hypertension > 180/110 mmhg or gastroesophageal reflux disease |
Show 1 more
Clinical
Clinical Trials
2062 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | 2 | 4 | 6 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | 1 | 2 | 3 |
| Coronary disease | D003327 | — | — | — | — | — | 1 | 2 | 3 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 1 | 2 | 3 |
| Coronary restenosis | D023903 | EFO_0004224 | — | — | — | — | 1 | 1 | 2 |
| Patent foramen ovale | D054092 | — | Q21.12 | — | — | 1 | 1 | — | 2 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | 1 | — | 1 |
| Coronary stenosis | D023921 | EFO_1000882 | — | — | — | — | 1 | — | 1 |
| Embolism | D004617 | — | — | — | — | — | 1 | — | 1 |
| Paradoxical embolism | D019320 | EFO_1001308 | — | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | — | — | — | — | 1 | — | 3 | 4 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | — | 3 | 4 |
| Dyslipidemias | D050171 | — | — | — | 1 | 2 | — | — | 3 |
| Flushing | D005483 | — | R23.2 | — | — | 2 | — | 1 | 3 |
| Dual anti-platelet therapy | D000080903 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | — | N19 | — | — | — | — | 2 | 2 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 2 | 2 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | — | — | 2 | 2 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | — | 2 | 2 |
| Hemorrhagic stroke | D000083302 | — | — | — | — | — | — | 2 | 2 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | — | — | — | 2 | 2 |
| Hemostatic disorders | D020141 | — | — | — | — | — | — | 2 | 2 |
| Coagulation protein disorders | D020147 | — | — | — | — | — | — | 2 | 2 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | — | 1 | 1 |
| Percutaneous coronary intervention | D062645 | — | — | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Aspirin |
| INN | carisoprodol |
| Description | Acetylsalicylic acid is a member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, a platelet aggregation inhibitor, an antipyretic, a cyclooxygenase 2 inhibitor, a cyclooxygenase 1 inhibitor, a prostaglandin antagonist, a teratogenic agent, an anticoagulant, a plant activator, an EC 1.1.1.188 (prostaglandin-F synthase) inhibitor, a drug allergen and a geroprotector. It is a member of benzoic acids, a member of salicylates and a member of phenyl acetates. It is functionally related to a salicylic acid. It is a conjugate acid of an acetylsalicylate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)Oc1ccccc1C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 50-78-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL25 |
| ChEBI ID | 15365 |
| PubChem CID | 2244 |
| DrugBank | DB00945 |
| UNII ID | R16CO5Y76E (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Vazalore – PLx Pharma
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 78,341 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ascomp with codeine, Butalbital, aspirin, caffeine and codeine phosphate, Clopidogrel kit, Darvon-n, Hydrocodone bitartrate and aspirin, Oxycodone and aspirin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
184,941 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use